Forte Biosciences Resultados de beneficios anteriores
Pasado controles de criterios 0/6
Forte Biosciences's earnings have been declining at an average annual rate of -2.4%, while the Biotechs industry saw earnings growing at 19% annually.
Información clave
-2.4%
Tasa de crecimiento de los beneficios
60.5%
Tasa de crecimiento del BPA
| Crecimiento de la industria Biotechs | 17.0% |
| Tasa de crecimiento de los ingresos | n/a |
| Rentabilidad financiera | -210.8% |
| Margen neto | n/a |
| Última actualización de beneficios | 30 Jun 2024 |
Actualizaciones de resultados anteriores recientes
Recent updates
We're A Little Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn Rate
Jul 17
Is Forte Biosciences (NASDAQ:FBRX) In A Good Position To Deliver On Growth Plans?
Mar 14Large Forte Biosciences shareholder scolds company board of directors
Aug 24We're Hopeful That Forte Biosciences (NASDAQ:FBRX) Will Use Its Cash Wisely
Aug 17Forte Biosciences: Lots Of Clinical Risk Ahead And A Questionable Business Plan
Aug 16Forte Biosciences large shareholders make demands for company's future
Jul 07We Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth Carefully
Dec 23Forte Biosciences files for $300M mixed shelf offering
May 28Are Insiders Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Stock?
Mar 13Do Institutions Own Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Jan 19
Forte Biosciences: FB-401 Potentially Best-In-Class In Atopic Dermatitis
Dec 18Who Has Been Buying Forte Biosciences, Inc. (NASDAQ:FBRX) Shares?
Nov 25Forte Biosciences readies equity offering
Oct 28Desglose de ingresos y gastos
Cómo gana y gasta dinero Forte Biosciences. Basado en los últimos beneficios reportados, en base a los últimos doce meses (LTM).
Historial de beneficios e ingresos
| Fecha | Ingresos | Beneficios | Gastos G+A | Gastos de I+D |
|---|---|---|---|---|
| 30 Jun 24 | 0 | -36 | 17 | 20 |
| 31 Mar 24 | 0 | -32 | 12 | 21 |
| 31 Dec 23 | 0 | -31 | 11 | 22 |
| 30 Sep 23 | 0 | -30 | 10 | 21 |
| 30 Jun 23 | 0 | -24 | 8 | 16 |
| 31 Mar 23 | 0 | -18 | 9 | 10 |
| 31 Dec 22 | 0 | -14 | 8 | 6 |
| 30 Sep 22 | 0 | -12 | 8 | 4 |
| 30 Jun 22 | 0 | -17 | 8 | 9 |
| 31 Mar 22 | 0 | -19 | 8 | 11 |
| 31 Dec 21 | 0 | -22 | 8 | 14 |
| 30 Sep 21 | 0 | -23 | 7 | 16 |
| 30 Jun 21 | 0 | -20 | 6 | 14 |
| 31 Mar 21 | 0 | -49 | 5 | 12 |
| 31 Dec 20 | 0 | -46 | 4 | 10 |
| 30 Sep 20 | 0 | -43 | 3 | 8 |
| 30 Jun 20 | 0 | -39 | 2 | 5 |
| 31 Mar 20 | 0 | -5 | 2 | 3 |
| 31 Dec 19 | 0 | -4 | 1 | 3 |
Ingresos de calidad: FBRX is currently unprofitable.
Margen de beneficios creciente: FBRX is currently unprofitable.
Análisis del flujo de caja libre vs. Beneficios
Análisis del crecimiento de los beneficios en el pasado
Tendencia de beneficios: FBRX is unprofitable, and losses have increased over the past 5 years at a rate of 2.4% per year.
Acelerando crecimiento: Unable to compare FBRX's earnings growth over the past year to its 5-year average as it is currently unprofitable
Beneficios vs. Industria: FBRX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-2.3%).
Rentabilidad financiera
Alta ROE: FBRX has a negative Return on Equity (-210.82%), as it is currently unprofitable.